TargetMol

(2S,3R)-Voruciclib hydrochloride

Product Code:
 
TAR-T10096L2
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10096L2-200mg200mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-5mg5mg£320.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-1mL1 mL * 10 mM (in DMSO)£348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-10mg10mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-50mg50mg£1,238.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10096L2-100mg100mg£1,662.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
(2S,3R)-Voruciclib hydrochloride is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.
CAS:
T10096L2
Formula:
C22H20Cl2F3NO5
Molecular Weight:
506.3
Purity:
0.98
SMILES:
Cl[H].ClC1=CC(C(F)(F)F)=CC=C1C(OC2=C(C(O)=CC(O)=C23)[C@H]([C@H]4CO)CCN4C)=CC3=O

References

1. Veena Agarwal, et al. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO2012123889A1.